Movement Disorder News and Research

Latest Movement Disorder News and Research

Amphetamine linked to development of Parkinson’s disease

New research suggests that taking prescription amphetamines may raise the risk of developing Parkinson’s disease later. But, the researchers noted that the study did not prove a cause-and-effect relationship and further investigation is warranted. The research was released Feb. 19, and is scheduled to be presented in April at the American Academy of Neurology’s annual meeting in Honolulu.

21 Feb 2011

Deep brain stimulation therapy promising against severe OCD

When obsessive-compulsive disorder is of crippling severity and drugs and behavior therapy can't help, there has been for just over a year a thread - or rather a wire - of hope. By inserting a thin electrode deep into the brain, doctors can precisely deliver an electrical current to a cord of the brain's wiring and soften the severity of the symptoms. "Deep brain stimulation" therapy for OCD won Food and Drug Administration approval in 2009 for extreme cases under its humanitarian device exemption.

19 Feb 2011

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

Ceregene, Inc., a biopharmaceutical company, reported today that its scientists and collaborators have published new experimental findings in support of its Parkinson's disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, i.e., neurturin or NRTN, intended to restore and preserve dying neurons.

17 Feb 2011

WINCS detects and measures serotonin levels in brain through deep brain stimulation

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System (WINCS) can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

16 Feb 2011

New research shows link between two pesticides and Parkinson's disease

New research shows a link between use of two pesticides, rotenone and paraquat, and Parkinson's disease. People who used either pesticide developed Parkinson's disease approximately 2.5 times more often than non-users.

14 Feb 2011

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy, an international study led by the University of South Florida found.

11 Feb 2011

DOPAL plays key role in killing dopamine neurons which trigger Parkinson's disease: Study

In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness.

10 Feb 2011

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

5 Feb 2011

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

The Salk Institute has been awarded a $2.3 million grant by the California Institute for Regenerative Medicine for translational research focusing on developing a novel stem cell based therapy for Parkinson's disease.

4 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

USF Health sponsors conference on Parkinson's disease and multiple sclerosis

Some of the country's leading physicians and researchers in the fields of Parkinson's disease and multiple sclerosis will gather later this month to discuss the latest advances in the diagnosis and treatment of these neurological disorders.

3 Feb 2011

Merz introduces new educational website for patients with focal dystonias

In support of the focal dystonia community, Merz Pharmaceuticals today announced the launch of a new educational website, FocalDystoniaExchange.com, where people affected by certain focal dystonias, as well as caregivers, family and friends, can learn more about the conditions and access helpful resources. For people who suffer from focal dystonias, completing simple, everyday tasks can be a difficult and challenging process.

3 Feb 2011

Brains of migraine sufferers show higher proportion of lesions of brain microvessels

Recent work, in particular the CAMERA study, has used MRI to study the brains of migraine sufferers and has shown that a higher proportion of these patients exhibit lesions of the brain microvessels than the rest of the population.

20 Jan 2011

Deep brain stimulation stabilizes motor symptoms in Parkinson's disease over time

Parkinson's disease symptoms begin subtly and worsen as damage to certain brain cells continues. But an electrical stimulation device implanted deep in the brain and programmed remotely, along with medications, may provide some control of "motor symptoms" common to the disease, such as shaking, stiffness, and loss of muscle control.

19 Jan 2011

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Pico-Tesla, The Magneceutical Company, announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa.

5 Jan 2011

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.

16 Dec 2010

African American patients less likely to receive medications for parkinsonian symptoms

African American patients and those with lower socioeconomic status have more advanced disease and greater disability when they seek treatment from Parkinson's disease specialists, according to a study from the University of Maryland School of Medicine.

14 Dec 2010

Research programs embody the promise of anti-aging medicine.

Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.

13 Dec 2010

IETF announces March as National Essential Tremor Awareness Month

The International Essential Tremor Foundation is proud to announce that the United States House of Representatives formally passed House Resolution 1264 sponsored by Congressman Dennis Moore officially designating the month of March as "National Essential Tremor Awareness Month".

10 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

Movement Disorder News and Research

Latest Movement Disorder News and Research

Amphetamine linked to development of Parkinson’s disease

Deep brain stimulation therapy promising against severe OCD

First evidence of neurotrophic factors improving status of degenerating dopamine neurons in Parkinson's brains

WINCS detects and measures serotonin levels in brain through deep brain stimulation

New research shows link between two pesticides and Parkinson's disease

Preladenant may offer new supplemental treatment for Parkinson's disease: Study

DOPAL plays key role in killing dopamine neurons which trigger Parkinson's disease: Study

WINCS device can detect and measure serotonin levels in brain: Mayo Clinic

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

USF Health sponsors conference on Parkinson's disease and multiple sclerosis

Merz introduces new educational website for patients with focal dystonias

Brains of migraine sufferers show higher proportion of lesions of brain microvessels

Deep brain stimulation stabilizes motor symptoms in Parkinson's disease over time

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

African American patients less likely to receive medications for parkinsonian symptoms

Research programs embody the promise of anti-aging medicine.

IETF announces March as National Essential Tremor Awareness Month

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Movement Disorder News and Research

Latest Movement Disorder News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in